CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV) announced today it has accepted the resignation of Dr. Curtis Wright, its Executive Vice President for Risk Management and Regulatory Affairs, for personal reasons. Dr. Wright will pursue a business opportunity outside the field of pain drug development that offers him the opportunity to work closer to his home and continue as a consultant to Javelin.
